HER2 testing in gastric cancer: results of a German expert meeting
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer and the correct use of first-line chemotherapy. While testing for HER2 status in breast cancer is routinely performed, this is not the case for HER2 testing in gastric cancer and it is usually only performed on clinician request. An interdisciplinary German expert group (pathologists and clinicians) took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication. The recommendations made in this manuscript reflect the consensus of all participants and reflect their opinions and long-term experience in this field.
Details
Original language | English |
---|---|
Pages (from-to) | 835-841 |
Number of pages | 7 |
Journal | Journal of cancer research and clinical oncology |
Volume | 143 |
Issue number | 5 |
Publication status | Published - 1 May 2017 |
Peer-reviewed | Yes |
External IDs
PubMed | 28285403 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Consensus, Gastric cancer, HER2 testing, Quality assurance, Trastuzumab